Skip to main content
SpringerLink
Log in

General Introduction

  • Chapter
  • First Online:
Progressive Multiple Sclerosis

  • 1930 Accesses

Abstract

Substantial advances in understanding disease processes in multiple sclerosis (MS) have occurred in recent years. Many susceptibility genes have been identified, complex immunological pathways have been mapped out, and rapid changes in imaging techniques have vastly added to our understanding of temporal changes occurring in the disease. Perhaps more significantly, powerful treatments are emerging with dramatic effects on relapse frequency, allowing the clinician an array of therapeutic options. Yet despite these advances, progressive MS remains difficult to treat and, once established, current drug therapies have little influence on the disease course of progressive MS. Patients with progressive disease are often frustrated by the lack of disease-modifying therapies (DMTs) and many will turn to alternative unproven treatments out of desperation. Clinicians too may feel powerless to halt the relentless progression of disability. Having said that, knowledge concerning the disease mechanisms is burgeoning and many research groups are starting to develop strategies to treat disease progression. At the heart of such strategies is an increasing knowledge of the pathophysiology of disease progression. This book will review the current state of knowledge concerning disease progression and put it in the context of developing and future therapies for this particular phase of MS. To set the scene, in this chapter some general features of MS, which will not be covered in subsequent chapters, and some brief recent updates in the broader field of MS will be presented.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. McDonald WI, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121–7.

    Article  PubMed  CAS  Google Scholar 

  2. Polman CH, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.

    Article  PubMed  Google Scholar 

  3. Ramagopalan SV, et al. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010;9(7):727–39.

    Article  PubMed  Google Scholar 

  4. Bronson PG, et al. CIITA variation in the presence of HLA-DRB1*1501 increases risk for multiple sclerosis. Hum Mol Genet. 2010;19(11):2331–40.

    Article  PubMed  CAS  Google Scholar 

  5. Lincoln MR, et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet. 2005;37(10):1108–12.

    Article  PubMed  CAS  Google Scholar 

  6. Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214–9.

    Article  PubMed  CAS  Google Scholar 

  7. International Multiple Sclerosis Genetics Consortium (IMSGC). Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci. Hum Mol Genet. 2010;19(5):953–62.

    Article  Google Scholar 

  8. Kurtzke JF. Geographic distribution of multiple sclerosis: an update with special reference to Europe and the Mediterranean region. Acta Neurol Scand. 1980;62(2):65–80.

    Article  PubMed  CAS  Google Scholar 

  9. van der Mei IA, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case–control study. BMJ. 2003;327(7410):316.

    Article  PubMed  Google Scholar 

  10. Munger KL, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296(23):2832–8.

    Article  PubMed  CAS  Google Scholar 

  11. Mowry EM, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol. 2010;67(5):618–24.

    PubMed  CAS  Google Scholar 

  12. van der Mei IA, et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol. 2007;254(5):581–90.

    Article  PubMed  Google Scholar 

  13. Simpson Jr S, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010;68(2):193–203.

    PubMed  CAS  Google Scholar 

  14. Lemire JM, et al. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr. 1995;125(6 Suppl):1704S–8.

    PubMed  CAS  Google Scholar 

  15. Ramagopalan SV, et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet. 2009;5(2):e1000369.

    Article  PubMed  Google Scholar 

  16. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81(3):353–73.

    Article  PubMed  CAS  Google Scholar 

  17. Sundstrom P, et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology. 2004;62(12):2277–82.

    Article  PubMed  CAS  Google Scholar 

  18. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol. 2007;61(4):288–99.

    Article  PubMed  Google Scholar 

  19. Salvetti M, Giovannoni G, Aloisi F. Epstein-Barr virus and multiple sclerosis. Curr Opin Neurol. 2009;22(3):201–6.

    Article  PubMed  Google Scholar 

  20. Niller HH, Wolf H, Minarovits J. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity. 2008;41(4):298–328.

    Article  PubMed  CAS  Google Scholar 

  21. Levin LI, et al. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA. 2005;293(20):2496–500.

    Article  PubMed  CAS  Google Scholar 

  22. Serafini B, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007;204(12):2899–912.

    Article  PubMed  CAS  Google Scholar 

  23. Willis SN, et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain. 2009;132(Pt 12):3318–28.

    Article  PubMed  Google Scholar 

  24. Thompson AJ, et al. A clinical and laboratory study of benign multiple sclerosis. Q J Med. 1986;58(225):69–80.

    PubMed  CAS  Google Scholar 

  25. Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry. 1999;67(2):148–52.

    Article  PubMed  CAS  Google Scholar 

  26. Poser S, Wikstrom J, Bauer HJ. Clinical data and the identification of special forms of multiple sclerosis in 1271 cases studied with a standardized documentation system. J Neurol Sci. 1979;40(2–3):159–68.

    Article  PubMed  CAS  Google Scholar 

  27. Costelloe L, et al. Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease. J Neurol Neurosurg Psychiatry. 2008;79(11):1245–8.

    Article  PubMed  CAS  Google Scholar 

  28. Correale J, Peirano I, Romano L. Benign multiple sclerosis: a new definition of this entity is needed. Mult Scler. 2012;18(2):210–8.

    Article  PubMed  Google Scholar 

  29. Scalfari A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010;133(Pt 7):1914–29.

    Article  PubMed  Google Scholar 

  30. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907–11.

    Article  PubMed  CAS  Google Scholar 

  31. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):655–61.

    Google Scholar 

  32. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498–504.

    Google Scholar 

  33. Johnson KP. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268–76.

    Article  PubMed  CAS  Google Scholar 

  34. Jacobs LD. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285–94.

    Article  PubMed  CAS  Google Scholar 

  35. Coles AJ. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786–801.

    Article  PubMed  Google Scholar 

  36. Polman CH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.

    Article  PubMed  CAS  Google Scholar 

  37. Cohen JA, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–15.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Frenchay Hospital, Frenchay Park Road, Bristol, BS16 1LE, UK

    Alastair Wilkins M.A., M.B., B.Chir, Ph.D., FRCP

Authors
  1. Alastair Wilkins M.A., M.B., B.Chir, Ph.D., FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alastair Wilkins M.A., M.B., B.Chir, Ph.D., FRCP .

Editor information

Editors and Affiliations

  1. , Department of Neurology, Frenchay Hospital, Frenchay Park Road, Bristol, BS16 1LE, United Kingdom

    Alastair Wilkins

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Wilkins, A. (2013). General Introduction. In: Wilkins, A. (eds) Progressive Multiple Sclerosis. Springer, London. https://doi.org/10.1007/978-1-4471-2395-8_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2395-8_1

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2394-1

  • Online ISBN: 978-1-4471-2395-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation